EBV-TCR-T Cells for EB Virus Infection After HSCT

Overview

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of EBV-TCR-T cells in patients with EB virus infection after HSCT.

Full Title of Study: “A Pilot Study of EBV-TCR-T Cells in EB Virus Infection Diseases After HSCT”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 1, 2021

Detailed Description

EBV infection is a common virus infection of HSCT, and which is highly related with the failure of transplantation and survival time of transplant patients. To evaluate the safety and efficacy of allogenic EBV-TCR-T cell therapy in subjects with EBV infection, patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*11012012402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Interventions

  • Biological: EBV-TCR-T cells
    • EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Arms, Groups and Cohorts

  • Experimental: EBV-TCR-T cells
    • Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of adverse events
    • Time Frame: 3months
    • Percentage of participants with adverse events.

Secondary Measures

  • Proliferation ratio of TCR-T cells
    • Time Frame: 3months
  • changes of EBV-DNA copies
    • Time Frame: 3months

Participating in This Clinical Trial

Inclusion Criteria

1. Age 1-70 years, including boundary values, gender unlimited;

2. The EBV DNA copies number of allogenic HSCT patients with EBV infection (EBV emia and EBV positive PTLD) still did not decrease,after treated with lower dosage of Immunosuppressants,or antiviral therapy or Rituximab(Rituxan);

3. Allogenic HSCT patients could not tolerate the antiviral therapy and / or Rituximab(Rituxan);

4. The EBV-positive diagnosis criteria: EBV DNA copy number>1000 copies/ ml, or the tissue EBV-EBER pathological result is positive, the diagnosis of PTLD was based on the diagnostic criteria of WHO 2016;

5. Estimated life expectancy ≥ 3 months;

6. ECOG 3 ;

7. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.

Exclusion Criteria

1. Patients with active aGVHD III-IV and / or mild and severe cGVHD;

2. Received cell therapy such as DLI,CTL,CAR-T or participated in any other clinical study of drugs and medical devices before 30 days of enrollment;

3. Pregnant or lactating women;

4. Intracranial hypertension or confusion; respiratory failure; disseminated intravascular coagulation;

5. patients with organ failure:

  • Heart: NYHA heart function grade IV;
  • Liver: Grade C that achieves Child-Turcotte liver function grading;
  • Kidney: kidney failure and uremia;
  • Lung: symptoms of respiratory failure;
  • Brain: a person with a disability;

6. The researchers found that it was unsuitable for the recipients to be enrolled.

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hebei Yanda Ludaopei Hospital
  • Collaborator
    • China Immunotech Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Xingyu Cao, PhD, +8619910757321, caoxingyu@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.